Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
[C3H4O2]x[C2H2O2]y
NACRES:
NA.23
UNSPSC Code:
12162002
Quality Level
form
amorphous
feed ratio
lactide:glycolide 50:50
mol wt
Mw 7,000-17,000
degradation timeframe
<3 months
viscosity
0.16-0.24 dL/g, 0.5 % (w/v) in chloroform(25 °C, Ubbelohde) (size 0c glass capillary viscometer)
transition temp
Tg 42-46 °C
shipped in
wet ice
storage temp.
2-8°C
Application
Resomer® RG 502 can be used to formulate a PLGA-based nano drug delivery system for the anti-inflammatory drug, 6-bromoindirubin-3′-glycerol-oxime ether (6BIGOE).
Itcan also be used to prepare control release formulations for Naloxone HCldelivery.
Itcan also be used to prepare control release formulations for Naloxone HCldelivery.
Features and Benefits
- Biocompatible
- Biodegradable
- Can be processed into almost any shape and size
- Tunable mechanical properties
Legal Information
Product of Evonik
RESOMER is a registered trademark of Evonik Rohm GmbH
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Teresa Musumeci et al.
International journal of pharmaceutics, 440(2), 135-140 (2012-10-20)
Melatonin, a neurohormone secreted by the pineal gland, is able to modulate intraocular pressure (IOP). The aim of this study was to generate nanoparticle (NPs) sustained release formulations that allow to extend the pre-corneal residence time of melatonin, thus prolonging
Maria Kirzhner et al.
Ophthalmology, 120(6), 1300-1304 (2013-02-13)
To compare wrapped and polymer-coated hydroxyapatite implants in children undergoing primary enucleation with no adjuvant therapies. Retrospective, interventional cohort study. All children undergoing primary enucleation without adjuvant therapies between 1999 and 2009 at a tertiary pediatric cancer hospital. Review and
Igor Jeroukhimov et al.
Journal of the American College of Surgeons, 218(1), 102-107 (2013-11-12)
Chronic pain after inguinal hernia repair occurs in 16% to 62% of patients. The underlying mechanism probably involves sensory nerve damage and abnormal healing that might be influenced by the materials chosen for the procedure. We hypothesize that nonabsorbable sutures